F2g.com - Novel Therapeutics for Rare Fungal Infections | F2G

Provided by Alexa ranking, f2g.com has ranked N/A in N/A and 6,750,578 on the world. f2g.com reaches roughly 457 users per day and delivers about 13,708 users each month. The domain f2g.com uses a Commercial suffix and it's server(s) are located in N/A with the IP number 136.244.82.232 and it is a .com domain.

WEBWHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. F2G is transforming the fight against rare, invasive fungal infections by developing novel antifungals that give patients another chance at life.

List of domain same IP 136.244.82.232

Keywords on this domain

f2g

Search Results related to f2g.com on Search Engine

Novel Therapeutics for Rare Fungal Infections | F2G
f2g.com

https://f2g.com/

WEBWHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. F2G is transforming the fight against rare, invasive fungal infections by developing novel antifungals that give patients another chance at life.

DA: 86 PA: 19 MOZ Rank: 16

F2G Receives Complete Response Letter from FDA for New …
globenewswire.com

https://www.globenewswire.com/news-release/2023/6/19/2690251/0/en/F2G-Receives-Complete-Response-Letter-from-FDA-for-New-Drug-Application-for-Olorofim-for-The-Treatment-of-Invasive-Fungal-Infections-Plans-Resubmission-With-Additional-Data-and-Ana.html

WEBJun 19, 2023 · MANCHESTER, United Kingdom, June 19, 2023 (GLOBE NEWSWIRE) -- F2G Ltd. today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New...

DA: 75 PA: 49 MOZ Rank: 38

F2G | LinkedIn
linkedin.com

https://www.linkedin.com/company/f2g

WEBF2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and...

DA: 24 PA: 85 MOZ Rank: 65

F2G Announces FDA Filing Acceptance of New Drug Application
globenewswire.com

https://www.globenewswire.com/news-release/2022/12/19/2575954/0/en/F2G-Announces-FDA-Filing-Acceptance-of-New-Drug-Application-for-Olorofim-for-the-Treatment-of-Invasive-Fungal-Infections.html

WEBPRINCETON, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- F2G Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for olorofim...

DA: 76 PA: 50 MOZ Rank: 37

F2G Announces FDA Filing Acceptance of New Drug Application …
yahoo.com

https://finance.yahoo.com/news/f2g-announces-fda-filing-acceptance-080000552.html

WEBPRINCETON, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- F2G Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for olorofim...

DA: 11 PA: 69 MOZ Rank: 67

A Scientific Breakthrough in Antifungal Treatments | F2G
f2g.com

https://f2g.com/science/

WEBA Scientific Breakthrough in Antifungal Treatments | F2G. Science. Uncovering a novel compound. Combining our expertise in fungal molecular biology and biochemistry, we identify and develop novel antifungal compounds.

DA: 82 PA: 96 MOZ Rank: 19

F2G: Receives Second US FDA Breakthrough Therapy …
fdahealthnews.com

https://fdahealthnews.com/stories/561292998-f2g-receives-second-us-fda-breakthrough-therapy-designation-for-olorofim

WEBOct 26, 2020 · F2G Ltd, a UK- and Austria-based biotech company developing novel therapies for life-threatening systemic fungal infections, announced today that the US Food and Drug Administration (FDA) has granted an additional Breakthrough Therapy Designation to its lead first-in-class candidate, olorofim, for the indication of 'Treatment …

DA: 21 PA: 26 MOZ Rank: 72

F2G and Shionogi Present Full Data Set from Pivotal Phase
globenewswire.com

https://www.globenewswire.com/news-release/2023/10/21/2764291/0/en/F2G-and-Shionogi-Present-Full-Data-Set-from-Pivotal-Phase-2b-Study-at-Trends-in-Medical-Mycology-TIMM-2023-Demonstrating-Positive-Therapeutic-Responses-in-Patients-with-Invasive-Fu.html

WEBOct 21, 2023 · MANCHESTER, United Kingdom and OSAKA, Japan, Oct. 21, 2023 (GLOBE NEWSWIRE) -- F2G Ltd. and Shionogi & Co., Ltd., today announced full results from the pivotal Phase 2b open-label study (Study...

DA: 32 PA: 94 MOZ Rank: 98

F2G raises $61M for late-phase antifungal R&D | Fierce Biotech
fiercebiotech.com

https://www.fiercebiotech.com/biotech/f2g-raises-61m-for-late-phase-antifungal-r-d

WEBAug 12, 2020 · Biotech. F2G raises $61M for late-phase antifungal R&D. By Nick Paul Taylor Aug 12, 2020 7:51am. antifungal drug venture capital (VC) Cowen Healthcare Investments. F2G has raised $60.8 million...

DA: 53 PA: 31 MOZ Rank: 77

We’re Driving Innovation in Antifungal Therapeutics | We Are F2G
f2g.com

https://f2g.com/culture/

WEBFunctional Fungal Genomics (F2G) is founded on a genomic technology platform that would ultimately pioneer the discovery and development of first-in-class antifungals. 2000 F2G harnesses their proprietary genomic technology platform and …

DA: 31 PA: 78 MOZ Rank: 96

Alexa Rank

GLOBAL RANK

6,750,578

Alexa Reach

0.0000201710

Page length

N/A

Alexa Rank Country N/A

N/A

Daily Unique Visitors

457

Monthly Unique Visitors

13,708

Vistor via Country

Country lang

Country code

Total visitor

Country

Country code

Total visitor

United States

2,932

Indonesia

2,293

Taiwan

746

United Kingdom

662

Brazil

599

Nigeria

524

Egypt

440

Hong Kong

415

Canada

415

Australia

362

Philippines

259

India

252

Malaysia

248

Spain

206

Germany

200

Mexico

192

France

181

Italy

167

Turkey

154

Iraq

140

Thailand

137

Netherlands

132

Israel

130

Cambodia

108

Algeria

Ireland

Romania

Jordan

Poland

Ghana

Argentina

South Africa

Belgium

Czechia

Ukraine

Japan

Morocco

South Korea

Lebanon

Saudi Arabia

Austria

Hungary

Sweden

Singapore

Pakistan

Bangladesh

Denmark

Greece

Alexa Traffic Graph

Alexa daily traffic trend graph

Alexa daily pageviews (percent) graph

Alexa Statistics Graph for www.nahklick.de

Alexa daily pageviews per user graph

Alexa time on site (in minutes) graph

Alexa bounce rate (percent) graph

Alexa search visits graph

SEOquake Zone

Title			Tips
Description			Tips
Keywords			Tips
Viewport			Tips
Icon
UTF-8

Mini site formation by Alexa Rank

MOZ Rank

Semcrush Traffic Graph

DNS Record

Host	Type	Class	TTL	Extra
f2g.com	A	IN	300	Ip: 136.244.82.232
f2g.com	SOA	IN	300	Mname: ns1.linode.com Rname: webmaster.elliptical.co.uk Serial: 2021000027 Refresh: 14400 Retry: 14400 Expire: 1209600 Minimum-ttl: 300
f2g.com	NS	IN	300	Target: ns1.linode.com
f2g.com	NS	IN	300	Target: ns3.linode.com
f2g.com	NS	IN	300	Target: ns2.linode.com
f2g.com	NS	IN	300	Target: ns5.linode.com
f2g.com	NS	IN	300	Target: ns4.linode.com
f2g.com	MX	IN	3600	Pri: 10 Target: eu-smtp-inbound-2.mimecast.com
f2g.com	MX	IN	3600	Pri: 10 Target: eu-smtp-inbound-1.mimecast.com
f2g.com	TXT	IN	300	Txt: qvmrlt0f70lvq4r0ll2tol28hq Entries_0: qvmrlt0f70lvq4r0ll2tol28hq
f2g.com	TXT	IN	300	Txt: MS=ms95018601 Entries_0: MS=ms95018601
f2g.com	TXT	IN	300	Txt: l7a00cbnpn5pghl5vuk673gi9s Entries_0: l7a00cbnpn5pghl5vuk673gi9s
f2g.com	TXT	IN	300	Txt: mhhQDRP7wuRxB5xZxgb78qgb5Tc Entries_0: mhhQDRP7wuRxB5xZxgb78qgb5Tc
f2g.com	TXT	IN	300	Txt: v=spf1 include:eu._netblocks.mimecast.com ip4:81.223.103.179/32 ip4:92.42.144.52/32 ip4:50.184.72.78/32 ip4:63.94.100.74/32 ip4:63.94.100.75/32 ip4:164.39.77.172/32 include:spf.protection.outlook.com -all Entries_0: v=spf1 include:eu._netblocks.mimecast.com ip4:81.223.103.179/32 ip4:92.42.144.52/32 ip4:50.184.72.78/32 ip4:63.94.100.74/32 ip4:63.94.100.75/32 ip4:164.39.77.172/32 include:spf.protection.outlook.com -all
f2g.com	TXT	IN	300	Txt: 0ed1fe018ab8709b3d39204de392c17ed073f4b3a9 Entries_0: 0ed1fe018ab8709b3d39204de392c17ed073f4b3a9
f2g.com	TXT	IN	300	Txt: k1341nl63pfnel5dlrqbh8vhuq Entries_0: k1341nl63pfnel5dlrqbh8vhuq

Hosting and Whois Zone

IP	136.244.82.232
Domain infomation	Domain Name: F2G.COM Registry Domain ID: 13674582_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2023-07-27T22:10:48Z Creation Date: 1999-11-22T16:43:27Z Registry Expiry Date: 2026-11-22T16:43:27Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: [email protected] Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS1.LINODE.COM Name Server: NS2.LINODE.COM Name Server: NS3.LINODE.COM Name Server: NS4.LINODE.COM Name Server: NS5.LINODE.COM DNSSEC: unsigned URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/ >>> Last update of whois database: 2024-04-19T20:00:08Z <<< For more information on Whois status codes, please visit https://icann.org/epp NOTICE: The expiration date displayed in this record is the date the registrar's sponsorship of the domain name registration in the registry is currently set to expire. This date does not necessarily reflect the expiration date of the domain name registrant's agreement with the sponsoring registrar. Users may consult the sponsoring registrar's Whois database to view the registrar's reported date of expiration for this registration. TERMS OF USE: You are not authorized to access or query our Whois database through the use of electronic processes that are high-volume and automated except as reasonably necessary to register domain names or modify existing registrations; the Data in VeriSign Global Registry Services' ("VeriSign") Whois database is provided by VeriSign for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. VeriSign does not guarantee its accuracy. By submitting a Whois query, you agree to abide by the following terms of use: You agree that you may use this Data only for lawful purposes and that under no circumstances will you use this Data to: (1) allow, enable, or otherwise support the transmission of mass unsolicited, commercial advertising or solicitations via e-mail, telephone, or facsimile; or (2) enable high volume, automated, electronic processes that apply to VeriSign (or its computer systems). The compilation, repackaging, dissemination or other use of this Data is expressly prohibited without the prior written consent of VeriSign. You agree not to use electronic processes that are automated and high-volume to access or query the Whois database except as reasonably necessary to register domain names or modify existing registrations. VeriSign reserves the right to restrict your access to the Whois database in its sole discretion to ensure operational stability. VeriSign may restrict or terminate your access to the Whois database for failure to abide by these terms of use. VeriSign reserves the right to modify these terms at any time. The Registry database contains ONLY .COM, .NET, .EDU domains and Registrars.